Effects of saffron and barberry on components of metabolic syndrome

Comparison of the effects of saffron (Crocus Sativus L.), Berberis vulgaris fruit extract, and placebo on components of metabolic syndrome in patients with metabolic syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112617756N11

Enrollment

Registered

2017-01-02

Start date

2007-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic disorder. Other metabolic disorders

Interventions

Intervention 1: The first intervention group (saffron group): tablets of 100 mg of crocin (constituent of saffron) one per day for 3 weeks. Intervention 2: The second intervention group (barberry grou

Treatment - Drugs

Placebo

The first intervention group (saffron group): tablets of 100 mg of crocin (constituent of saffron) one per day for 3 weeks

The second intervention group (barberry group): three tablets of 550 mg Berberis vulgaris fruits extract per day for three weeks

The placebo group: starch tablets one per day for three weeks

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 30 and 60 years; individuals with metabolic syndrome defined by the Adult Treatment Panel III (ATP III); provision of informed consent; absence of any history of major cardiac, pulmonary, hepatic, gastroenterological, neurologic, psychiatric, or renal disease; non-pregnancy; Exclusion criterion: Unwillingness to continue participation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Body Mass Index. Timepoint: Before intervention and three weeks after intervention. Method of measurement: a Seca 200 scale with attached stadiometer.;Hypertension. Timepoint: Before intervention and three weeks after intervention. Method of measurement: mercury sphygmomanometer.;Fasting blood sugar (FBS). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun kit.;Triglyceride (TG). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.;Total cholesterol (Chol). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.;Low- and high-density lipoprotein (LDL and HDL). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.	—

Measure

Time frame

Body Mass Index. Timepoint: Before intervention and three weeks after intervention. Method of measurement: a Seca 200 scale with attached stadiometer.;Hypertension. Timepoint: Before intervention and three weeks after intervention. Method of measurement: mercury sphygmomanometer.;Fasting blood sugar (FBS). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun kit.;Triglyceride (TG). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.;Total cholesterol (Chol). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.;Low- and high-density lipoprotein (LDL and HDL). Timepoint: Before intervention and three weeks after intervention. Method of measurement: ParsAzmun Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Tooba Kazemi

Birjand University of Medical Sciences

drtooba.kazemi@gmail.com+98 56 3239 1200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026